Your email has been successfully added to our mailing list.

×
0 0 0 0.0227272727272727 0.0227272727272727 0.0227272727272727 0.0227272727272727 0.0227272727272727
Stock impact report

New Research Study Provides Target Validation for Mateon’s First-in-Class RNA Therapeutic OT101 for the Treatment of Difficult to Treat Forms of Childhood Brain Tumor

MATEON THERAPEUTICS (MATN) 
Last mateon therapeutics earnings: 11/19 05:25 pm Check Earnings Report
US:NASDAQ Investor Relations: investor.mateon.com
Company Research Source: GlobeNewswire
AGOURA HILLS, Calif., Oct. 23, 2019 (GLOBE NEWSWIRE) -- Oncotelic Inc. (“Oncotelic”), a wholly owned subsidiary of Mateon Therapeutics Inc. (OTCQB:MATN) dedicated to the development of innovative treatments for cancer, announced today the publication of a peer-reviewed research article authored by Fatih Uckun MD PhD and his colleagues at Oncotelic in the Journal of Clinical Research in Pediatrics (https://asclepiusopen.com/clinical-research-in-pediatrics/volume-2-issue-1/).  The article titled “In silico Molecular Target Validation Demonstrates Transforming Growth Factor Beta 2 is Strongly Expressed in Pediatric Diffuse Intrinsic Pontine Glioma and Glioblastoma Multiforme" demonstrates the therapeutic potential of Mateon’s first-in-class RNA therapeutic OT101 for the treatment of diffuse intrinsic pontine glioma (DIPG) and pediatric glioblastoma multiforme (GBM).  Citation Reference:  Uckun FM, Trieu V, Hwang L, Qazi S. In silico Molecular Target Validation Demonstrates Transformin Show less Read more
Impact Snapshot
Event Time:
MATN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last Price
VWAP
High:
Max Up
High:
Low:
Max Down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Opt-in for MATN alerts
Opt-in for
MATN alerts

from News Quantified
Opt-in for
MATN alerts

from News Quantified